WO2007000642A1 - Fluoroprostaglandins nitroderivatives - Google Patents
Fluoroprostaglandins nitroderivatives Download PDFInfo
- Publication number
- WO2007000642A1 WO2007000642A1 PCT/IB2006/001728 IB2006001728W WO2007000642A1 WO 2007000642 A1 WO2007000642 A1 WO 2007000642A1 IB 2006001728 W IB2006001728 W IB 2006001728W WO 2007000642 A1 WO2007000642 A1 WO 2007000642A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- formula
- integer
- compound
- ono
- Prior art date
Links
- 150000002828 nitro derivatives Chemical class 0.000 title abstract description 9
- 206010018307 Glaucoma and ocular hypertension Diseases 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 95
- -1 phenoxymethyl group Chemical group 0.000 claims description 70
- 229910004679 ONO2 Inorganic materials 0.000 claims description 44
- 150000003254 radicals Chemical group 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 208000010412 Glaucoma Diseases 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 206010030043 Ocular hypertension Diseases 0.000 claims description 5
- 239000002876 beta blocker Substances 0.000 claims description 5
- 229940097320 beta blocking agent Drugs 0.000 claims description 5
- 230000004410 intraocular pressure Effects 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 claims description 4
- 239000001301 oxygen Chemical group 0.000 claims description 4
- 125000006053 2-methyl-3-pentenyl group Chemical group 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 2
- 125000000301 2-(3-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 239000000048 adrenergic agonist Substances 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 229960004605 timolol Drugs 0.000 claims description 2
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003259 prostaglandin group Chemical group 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 description 56
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 15
- 229910002651 NO3 Inorganic materials 0.000 description 15
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000003960 organic solvent Substances 0.000 description 14
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 0 CC(C)CC(C)CCNCC1*C1 Chemical compound CC(C)CC(C)CCNCC1*C1 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000003180 prostaglandins Chemical class 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 229910001961 silver nitrate Inorganic materials 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 6
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- IIPYXGDZVMZOAP-UHFFFAOYSA-N lithium nitrate Chemical compound [Li+].[O-][N+]([O-])=O IIPYXGDZVMZOAP-UHFFFAOYSA-N 0.000 description 6
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 6
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 150000004820 halides Chemical class 0.000 description 5
- 229910017604 nitric acid Inorganic materials 0.000 description 5
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 5
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Substances ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 3
- IKDHVMDABUMCLO-UHFFFAOYSA-N 4-bromobutyl nitrate Chemical compound [O-][N+](=O)OCCCCBr IKDHVMDABUMCLO-UHFFFAOYSA-N 0.000 description 3
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000001785 ferulic acid Nutrition 0.000 description 3
- 229940114124 ferulic acid Drugs 0.000 description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000010333 potassium nitrate Nutrition 0.000 description 3
- 239000004323 potassium nitrate Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 235000010344 sodium nitrate Nutrition 0.000 description 3
- 239000004317 sodium nitrate Substances 0.000 description 3
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 2
- KIQXRQVVYTYYAZ-VKVYFNERSA-N (z)-7-[(1r,2r,3r,5s)-2-[(e)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoic acid Chemical compound OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 KIQXRQVVYTYYAZ-VKVYFNERSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- SIJLYRDVTMMSIP-UHFFFAOYSA-N 4-Bromo-1-butanol Chemical compound OCCCCBr SIJLYRDVTMMSIP-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 125000003031 C5-C7 cycloalkylene group Chemical group 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002497 iodine compounds Chemical class 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- HVFSJXUIRWUHRG-UHFFFAOYSA-N oic acid Natural products C1CC2C3CC=C4CC(OC5C(C(O)C(O)C(CO)O5)O)CC(O)C4(C)C3CCC2(C)C1C(C)C(O)CC(C)=C(C)C(=O)OC1OC(COC(C)=O)C(O)C(O)C1OC(C(C1O)O)OC(COC(C)=O)C1OC1OC(CO)C(O)C(O)C1O HVFSJXUIRWUHRG-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 229960004458 tafluprost Drugs 0.000 description 2
- WSNODXPBBALQOF-VEJSHDCNSA-N tafluprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COC1=CC=CC=C1 WSNODXPBBALQOF-VEJSHDCNSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- VSOJWGJCPFPODA-UHFFFAOYSA-N 1,3-dinitropropane-1,2,3-triol Chemical class [O-][N+](=O)C(O)C(O)C(O)[N+]([O-])=O VSOJWGJCPFPODA-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- QPLJYAKLSCXZSF-UHFFFAOYSA-N 2,2,2-trichloroethyl carbamate Chemical compound NC(=O)OCC(Cl)(Cl)Cl QPLJYAKLSCXZSF-UHFFFAOYSA-N 0.000 description 1
- HWUYVJQCOGRRGQ-UHFFFAOYSA-N 4-bromobutan-1-ol;oxolane Chemical compound C1CCOC1.OCCCCBr HWUYVJQCOGRRGQ-UHFFFAOYSA-N 0.000 description 1
- IWKLPOJPPIBQHO-FNORWQNLSA-N 4-bromobutyl (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound COC1=CC(\C=C\C(=O)OCCCCBr)=CC=C1O IWKLPOJPPIBQHO-FNORWQNLSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical class ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Chemical group 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical class [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 229960000722 brinzolamide Drugs 0.000 description 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 201000005682 chronic closed-angle glaucoma Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical class C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 230000003101 melanogenic effect Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 description 1
- 229960004317 unoprostone Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Definitions
- the present invention relates to new flouroprostaglandins nitroderivatives, pharmaceutical compositions containing them and their use as drugs for treating glaucoma and ocular hypertension.
- Glaucoma is optic nerve damage, often associated with increased intraocular pressure (lOP), that leads to progressive, irreversible loss of vision.
- lOP intraocular pressure
- Glaucoma occurs when an imbalance in production and drainage of fluid in the eye (aqueous humor) increases eye pressure to unhealthy levels.
- elevated IOP can be at least partially controlled by administering drugs which either reduce the production of aqueous humor within the eye or increase the fluid drainage, such as beta-blockers, ⁇ -agonists, cholinergic agents, carbonic anhydrase inhibitors, or prostaglandin analogs.
- drugs which either reduce the production of aqueous humor within the eye or increase the fluid drainage, such as beta-blockers, ⁇ -agonists, cholinergic agents, carbonic anhydrase inhibitors, or prostaglandin analogs.
- Topical beta-blockers show serious pulmonary side effects, depression, fatigue, confusion, impotence, hair loss, heart failure and bradycardia.
- Topical ⁇ -agonists have a fairly high incidence of allergic or toxic reactions; topical cholinergic agents (miotics) can cause visual side effects.
- oral carbonic anhydrase inhibitors include fatigue, anorexia, depression, paresthesias and serum electrolyte abnormalities (The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, M. H. Beers and R. Berkow Editors, Sec. 8, Ch. 100).
- topical prostaglandin analogs used in the treatment of glaucoma, can produce ocular side effects, such as increased pigmentation of the iris, ocular irritation, conjunctival hyperaemia, ulceris, uveitis and macular oedema (Martindale, Thirty-third edition, p. 1445)
- U.S. Pat. No. 3,922,293 describes monocarboxyacylates of prostaglandins F-type and their 15 ⁇ isomers, at the C-9 position, and processes for preparing them;
- U.S. Pat. No. 6,417,228 discloses 13-aza prostaglandins having functional PGF 2 ⁇ receptor agonist activity and their use in treating glaucoma and ocular hypertension.
- WO 90/02553 discloses the use of prostaglandins derivatives of PGA, PGB, PGE and PGF, in which the omega chain contains a ring structure, for the treatment of glaucoma or ocular hypertension.
- WO 00/51978 describes novel nitrosated and/or nitrosylated prostaglandins, in particular novel derivatives of PGE-i, novel compositions and their use for treating sexual dysfunctions.
- U.S. Pat. No. 5,625,083 discloses dinitroglycerol esters of prostaglandins which may be used as vasodilators, antihypertensive cardiovascular agents or bronchodilators.
- U.S. Pat. No. 6,211 ,233 discloses compounds of the general formula A-X 1 -NO 2 , wherein A contains a prostaglandin residue, in particular PGE 1 , and X 1 is a bivalent connecting bridge, and their use for treating impotence.
- U.S. Pat. No. 5,985,920 and U.S. Pat. No. 5,886,035 disclose 15-deoxy-15,15- difluoro-prostaglandins-F 2 ⁇ derivatives and their use in the treatment of glaucoma or ocular hypertension.
- the results of the pharmacological testes reported in the documents show that these fluoroPGF 2 ⁇ have a long-lasting effect of lowering intraocular pressure and they have a little effect on melanogenesis.
- tafluprost which is a 15-deoxy-15,15-difluoro-prostaglandin-F 2 ⁇ derivative.
- the results of the pharmacological tests demonstrate that tafluprost has a high lOP-reducing efficacy and weak melanogenic side effect.
- An object of the present invention is, therefore, fluoroprostaglandins nitroderivatives of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof
- R is the prostaglandin residue of formula (II):
- R 1 is selected from:
- aryloxyalkyl group optionally substituted on the aryl moiety with from 1 to 3 halogen atoms or haloalkyl groups; the carbon number of the alkyl moiety of the aryloxyalkyl group (i.e.
- the alkylene group is preferably from 1 to 3;
- the preferred aryloxyalkyl groups are: a phenoxymethyl group, a 3-chlorophenoxymethyl group, a 3-fluorophenoxymethyl group, a 3- (trifluoromethyl) phenoxymethyl group, a 3,5-dichlorophenoxymethyl group, a 3,4- dichlorophenoxymethyl group, a 3,5-difluorophenoxy methyl group, 3,4- difluorophenoxymethyl group, 3,5-bis(trifluoromethyl)phenoxymethyl group and 3,4- bis(trifluoromethyl)phenoxymethyl group;
- aralkyl group optionally substituted on the aryl moiety with from 1 to 3 halogen atoms or haloalkyl groups or alkoxy groups; the carbon number of the alkyl moiety of the aralky group (i.e.
- the alkylene group is preferably from 1 to 4;
- the preferred aralkyl groups are: a phenylmethyl group, a 2-phenylethyl group, a 3-methylphenylmethyl group, a 2-(3- methylphenyl)ethyl group, 3-(trifluoromethyl) phenylmethyl group, 2-(3- trifluoromethylphenyl)ethyl group, a 3-chlorophenylmethyl group, a 2-(3-chlorophenyl)ethyl group, 2-(3,4-dichlorophenyl)ethyl group or 2-(3,5-dichlorophenyl)ethyl group;
- R 1 is a C 5 -C 6 alkyl group substituted with one or two methyl group and selected from the group comprising: n-pentyl, 2-methylhexyl, 1,1-dimethylpentyl, 2-methypentyl, 2-methylhexyl;
- R-i is a C 5 -C 6 alkenyl group substituted with one or two methyl group selected from the group comprising: 1-metyl-3- pentenyl, 1-methyl-3-hexenyl, 1 ,1-dimethyl-3-hexenyl, 2-methyl-3-pentenyl; a C 3 -C 8 alkynyl group optionally substituted with halogen atoms, a C 1 -C 4 linear or branched alkyl group, a C 5 -C 6 cycloalkyl group, a C 1 -C 4 alkoxy group, a sulfur atom-
- each of R 2 and R 3 which are independent of one another is a hydrogen atom or an aliphatic hydrocarbon type C 2 -C 2O acyl group, preferably R 2 and R 3 are hydrogen atoms; each of R 4 and R 5 which are independent of one another, is an hydrogen atom or a fluorine atom with the proviso that at least one of R 4 and R 5 is a fluorine atom, preferably R 4 and R 5 are fluorine atoms;
- X is -O-, -S- or -NR 1 -, wherein R 1 is H or linear or branched C 1 -C 6 alkyl; m is an integer equal to 0 or 1 , with the proviso that m is equal to 0 when X is -O- or -S-; B is a radical of the formula -CH(R 1 )COO-, wherein R 1 is as above defined; Y is a bivalent radical having the following meanings: a) straight or branched C 1 -C 20 alkylene, preferably C 1 -Ci O , being optionally substituted with one or more of the substituents selected from the group consisting of: halogen atoms, hydroxy, -ONO 2 or T, wherein T is -OC(O)(C 1 -C 10 alkyl)-ONO 2 or -0(C 1 -C 10 alkyl)-ONO 2 ;
- n is an integer from 0 to 20, preferably n is an integer from 0 to 5; and n 1 is an integer from 1 to 20, preferably n 1 is an integer from 1 to 5; d)
- X 1 -OCO- or -COO- and R 2 is H or CH 3 ;
- Z is -(CH) n 1 - or the bivalent radical defined above under b) n 1 is as defined above and n 2 is an integer from O to 2; e)
- n 1 and R 2 are as defined above, R 3 is H or -COCH 3 ; with the proviso that the -ONO 2 group of formula (I) is bound to -(CH 2 ) n 1 ; and with the proviso that when X is -NR 1 -, wherein R 1 is as above defined Y cannot be f); g)
- n 3 is an integer from 1 to 6, preferably from 1 to 4, and R 2 is as defined above; h)
- R 4 , R 5 , R 6 , R 7 are the same or different, and are H or straight or branched C 1 -C 4 alkyl, preferably R 4 , R 5 , R 6 , R 7 are H; wherein the -ONO 2 group of formula (I) is linked to
- n is as defined above;
- Y 2 is an heterocyclic saturated, unsaturated or aromatic 5 or 6 members ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulfur, and is selected from
- C 1 -C 2O alkylene refers to branched or straight C 1 -C 20 hydrocarbon chain, preferably having from 1 to 10 carbon atoms such as methylene, ethylene, propylene, isopropylene, n-butylene, pentylene, n-hexylene and the like.
- CrCio alkyl refers to branched or straight alkyl groups comprising 1 to 10 carbon atoms, including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, octyl and the like.
- cycloalkylene refers to ring having from 5 to 7 carbon atoms including, but not limited to, cyclopentylene, cyclohexylene optionally substituted with side chains such as straight or branched (CrC 10 )-alkyl, preferably CH 3 .
- heterocyclic refers to saturated, unsaturated or aromatic 5 or 6 members ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulphur, such as for example pyridine, pyrazine, pyrimidine, pyrrolidine, morpholine, imidazole and the like.
- aryloxyalkyl group refers to groups wherein the aryl moiety is, for example, a benzene ring, a furan ring, a thiophene ring or a naphthalene ring and may have from 1 to 3 halogen atoms, haloalkyl groups, alkoxy groups or hydroxyl groups as substituents on the aryl moiety.
- the aryl moiety is preferably a phenyl group which is not substituted or substituted with from 1 to 3 halogen atoms or haloalkyl groups.
- the carbon number of the alkyl moiety (i.e. the alkylene group) of the aryloxyalkyl group is from 1 to 3.
- aralkyl group refers to groups wherein the aryl moiety is, for example, a benzene ring, a furan ring, a thiophene ring or a naphthalene ring and may be substituted with from 1 to 3 halogen atoms, haloalkyl groups, alkoxy groups or hydroxyl groups.
- the carbon number of the alkyl moiety substituted with the aryl group is preferably from 1 to 4.
- the invention includes also the pharmaceutically acceptable salts of the compounds of formula (I) and stereoisomers thereof.
- Examples of pharmaceutically acceptable salts are either those with inorganic bases, such as sodium, potassium, calcium and aluminium hydroxides, or with organic bases, such as lysine, arginine, triethylamine, dibenzylamine, piperidine and other acceptable organic amines.
- the compounds according to the present invention when they contain in the molecule one salifiable nitrogen atom, can be transformed into the corresponding salts by reaction in an organic solvent such as acetonitrile, tetrahydrofuran with the corresponding organic or inorganic acids.
- organic acids are: oxalic, tartaric, maleic, succinic, citric acids.
- Examples of inorganic acids are: nitric, hydrochloric, sulphuric, phosphoric acids. Salts with nitric acid are preferred.
- the compounds of the invention which have one or more asymmetric carbon atoms can exist as optically pure enantiomers, pure diastereomers, enantiomers mixtures, diastereomers mixtures, enantiomer racemic mixtures, racemates or racemate mixtures.
- Preferred compounds of formula (I) are those wherein_the fluoroprostaglandin precursor is selected from the following moieties R of formula (II) wherein: - the bond between the carbon atoms in positions 13 and 14 is a double bond; R 1 is a phenoxymethyl group; R 2 and R 3 are hydrogen atoms; R 4 and R 5 are fluorine atoms; or
- Ri is a 3-chlorophenoxymethyl group
- R 2 and R 3 are hydrogen atoms; R 4 and R 5 are fluorine atoms; or
- R 1 is a phenoxymethyl group
- R 2 and R 3 are hydrogen atoms
- R 4 and R 5 are fluorine atoms
- R 1 is a 3-chlorophenoxymethyl group
- R 2 and R 3 are hydrogen atoms;
- R 4 and R 5 are fluorine atoms;
- X is -O- or -NR 1 -, wherein R 1 is H or C 1 -C 6 alkyl, preferably R 1 is H or methyl; m is an integer equal to 0 or 1 , with the proviso that m is equal to 0 when X is -O-; B is a radical of the formula -CH(R 1 )COO-, wherein R 1 is as above defined; Y is a bivalent radical having the following meanings: a) straight or branched C 1 -C 20 alkylene, preferably C 1 -C 10 , being optionally substituted by one or more of the substituents selected from the group consisting of: halogen atoms, hydroxy, -ONO 2 or T 1 wherein T is
- n is an integer from 0 to 20, preferably n is an integer from 0 to 5; and n 1 is an integer from 1 to 20, preferably n 1 is an integer from 1 to 5; d)
- X 1 -OCO- or -COO- and R 2 is H or CH 3 ;
- Z is -(CH) n 1 - or the bivalent radical defined above under b) n 1 is as defined above and n 2 is an integer from 0 to 2; e)
- n 1 and R 2 are as defined above, R 3 is H or -COCH 3 ; with the proviso that the -ONO 2 group of formula (I) is bound to -(CH 2 ) ⁇ 1 ; and with the proviso that when X is -NR 1 -, wherein R 1 is as above defined, Y cannot be f); g)
- X 2 is -O- or -S-; n 3 is an integer from 1 to 6, preferably from 1 to 4, and R 2 is as defined above; h)
- R 4 , R 5 , R 6 , R 7 are the same or different, and are H or straight or branched C 1 -C 4 alky!, preferably R 4 , R 5 , R 6 , R 7 are H; wherein the -ONO 2 group of formula (I) is linked to wherein n 5 is as defined above;
- Y 2 is an heterocyclic saturated, unsaturated or aromatic 5 or 6 members ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulfur, and is selected from
- Y 2 is selected from:
- X is -O-, S or -NR 1 -, wherein R 1 is H or C 1 -C 6 alkyl, preferably R 1 is H or methyl; m is an integer equal to 0 or 1 , with the proviso that m is equal to 0 when X is -O- or S; B is a radical of the formula -CH(R 1 )COO-, wherein R 1 is as above defined; Y is a bivalent radical having the following meanings: a)
- n is an integer from O to 20, preferably from 0 to 5; and n 1 is an integer from 1 to 20, preferably from 1 to 5; d)
- X 1 -OCO- or -COO- and R 2 is H or CH 3 ;
- Z is -(CH) n 1 - or the bivalent radical defined above under b) wherein n is an integer from O to 5; n 1 is an integer from 1 to 5; and n 2 is an integer from O to 2; e) wherein:
- n 1 and R 2 are as defined above, R 3 is H or COCH 3 ; with the proviso that the -ONO 2 group of formula (I) is bound to -(CH 2 ) n 1 ; and with the proviso that when X is -NR 1 -, wherein R 1 is as above defined, Y cannot be f); g)
- n is an integer from 1 to 4; R 2 is hydrogen; h)
- n 4 is an integer from 0 to 10, preferably from 0 to 3; n s is an integer from 1 to 10, preferably from 1 to 3; R 4 , R 5 , R 6 , R 7 are the same and are H; and wherein the -ONO 2 group of formula (I) is linked to
- Y 2 is a 6 member saturated, unsaturated or aromatic heterocyclic ring, containing one or two atoms of nitrogen and selected from
- the compounds of the present invention can be synthesized as follows.
- Ri is as above defined; P is H or a hydroxylic protecting group; W is -OH, Cl, or -OC(O)Ri wherein R 1 is a linear or branched C 1 -C 5 alkyl; with a compound of formula (IV) Z a -(B) m -Y-Q
- Q is -ONO 2 or Zi wherein Z 1 is selected from the group consisting of: a chlorine atom, a bromine atom, a iodine atom, a mesyl group or a tosyl group; in the presence of a condensing agent, and b) when Q is Z 1 , by converting the compound obtained in the step a) into a nitro derivative by reaction with a nitrate source. c) optionally deprotecting the compounds obtained in step a) or b).
- Preferred hydroxylic protecting groups are silyl ethers, such as trimethylsilyl, tert-butyl- dimethylsilyl, or acetyl and those described in T. W. Greene "Protective groups in organic synthesis", Harvard University Press, 1980.
- a condensing agent such as N 1 N'- carbonyldiimidazole (CDI) or dicyclohexylcarbodiimide (DCC), N'-(3-dimethylaminopropyl) - N-ethylcarbodiimide hydrochlo ride
- the reaction is carried out in a dry inert organic solvent such as N 1 N'- dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon.
- a dry inert organic solvent such as N 1 N'- dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon.
- the reaction temperature is from -20 0 C to +4O 0 C.
- the reaction is completed within a time range from 30 minutes to 36 hours.
- a catalyst such as N 1 N- dimethylamino pyridine (DMAP).
- DMAP N 1 N- dimethylamino pyridine
- the reaction is carried out in an inert organic solvent such as N.N'-dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon.
- the reaction temperature is from -20°C to +4O°C.
- the reaction is completed within a time range from 30 minutes to 36 hours.
- a organic base such as N,N-dimethylamino pyridine (DMAP), triethylamine, pyridine.
- DMAP N,N-dimethylamino pyridine
- the reaction is carried out in an inert organic solvent such as N,N'-dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon.
- the reaction temperature is from -2O 0 C to 4O 0 C.
- the reaction is completed within a time range from 30 minutes to 36 hours.
- the preferred organic bases are for example 1 ,8-diazabiciclo[5.4.0]undec-7-ene (DBU), N,N-diisopropyl ethylamine, diisopropylamine; preferred inorganic base are alkaline- earth metal carbonate or hydroxide, potassium carbonate, cesium carbonate.
- DBU 1,8-diazabiciclo[5.4.0]undec-7-ene
- preferred inorganic base are alkaline- earth metal carbonate or hydroxide, potassium carbonate, cesium carbonate.
- the reaction is carried out in an inert organic solvent such as N,N'-dimethylformamide, tetrahydrofuran, acetone, methyl ethyl ketone, acetonitrile, a polyhalogenated aliphatic hydrocarbon.
- the reaction temperature is from -20°C to +40°C, preferably from 5 0 C to 25°C.
- the reaction is completed within a time range from 1 to 8 hours.
- Z 1 is a chlorine atom or a bromine atom the reaction is carried out in presence an iodine compound such as Kl.
- the nitrate source may be silver nitrate, lithium nitrate, sodium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, iron nitrate, zinc nitrate or tetraalkylammonium nitrate (wherein alkyl is C 1 -C 10 alkyl).
- the reaction is carried out in the dark and in a suitable organic solvent such as acetonitrile, tetrahydrofurane, methyl ethyl ketone, ethyl acetate, DMF.
- a suitable organic solvent such as acetonitrile, tetrahydrofurane, methyl ethyl ketone, ethyl acetate, DMF.
- Preferred nitrate source is silver nitrate.
- Step c) the protected hydroxyl groups can be converted to hydroxyl groups by methods described in T. W. Greene "Protective groups in organic synthesis", Harvard University Press, 1980. Fluoride ion is the preferred method for removing silyl ether protecting group.
- a chloroformate such as isobutylchloroformate, ethylchloroformate in presence of a non- nucleophilic base such as triethylamine in an inert organic solvent such as N 1 N'- dimethylformamide, tetrahydrofuran, a polyhalogenated aliphatic hydrocarbon at a temperature from -20°C and 40°C.
- the nitrate source may be silver nitrate, lithium nitrate, sodium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, iron nitrate, zinc nitrate or tetraalkylammonium nitrate (wherein alkyl is C 1 -C 10 alkyl).
- Preferred nitrate source is silver nitrate.
- the reaction is carried out in the dark and in a suitable organic solvent such as acetonitrile, tetrahydrofurane, methyl ethyl ketone, ethyl acetate, DMF.
- the reaction temperature is from room temperature to the boiling temperature of the solvent.
- the reaction temperature is usually from -5O 0 C to 0°C.
- the nitrate source may be silver nitrate, lithium nitrate, sodium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, iron nitrate, zinc nitrate or tetraalkylammonium nitrate (wherein alky! is C 1 -C 10 alkyl).
- Preferred nitrate source is silver nitrate.
- the reaction is carried out in the dark and in a suitable organic solvent such as acetonitrile, tetrahydrofurane, methyl ethyl ketone, ethyl acetate, DMF.
- a suitable organic solvent such as acetonitrile, tetrahydrofurane, methyl ethyl ketone, ethyl acetate, DMF.
- the reaction temperature is from room temperature to the boiling temperature of the solvent.
- the compound of formula (IVb) wherein Z a , Y and 2i are as above defined, can be synthesized h) by reacting a compound of formula (IVb')
- the compounds of formula (IVb') wherein Z a and Y are as above defined are commercially available or can be synthesized by processes well known in the art.
- the reaction temperature is usually from -50 0 C to O 0 C.
- Z 3 -Y-Q (Vl) wherein Z 3 is HO or Z 1 , Y Q and Z 1 are as above defined, and
- Preferred protecting groups for a amino group are for example tert-butylcarbamate (BOC), such as 2,2,2-trichloroethyl carbamate (TROC) and those described in T. W. Greene
- a dehydrating agent as dicyclohexylcarbodiimide (DCC) or N'-(3-dimethylaminopropyl)-N- ethylcarbodiimide hydrochloride (EDAC)
- DMAP N,N-dimethylamino pyridine
- the reaction is carried out in a dry inert organic solvent such as N 1 N'- dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon.
- a dry inert organic solvent such as N 1 N'- dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon.
- the reaction temperature is from -20 0 C to +40 0 C.
- the reaction is completed within a time range from 30 minutes to 36 hours.
- a catalyst such as N,N-dimethylamino pyridine (DMAP).
- DMAP N,N-dimethylamino pyridine
- the reaction is carried out in an inert organic solvent such as N 1 N'- dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon.
- the reaction temperature is from -2O 0 C to +40 0 C.
- the reaction is completed within a time range from 30 minutes to 36 hours.
- the reaction temperature is from -2O 0 C to +40°C, preferably from 5°C to +25°C.
- the reaction is completed within
- the reaction is carried out in an inert organic solvent such as N 1 N'- dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon.
- the reaction temperature is from -20 0 C to +4O 0 C.
- the reaction is completed within a time range from 30 minutes to 36 hours.
- a chloroformate such as isobutylchloroformate, ethylchloroformate in presence of a non-nucleophilic base such as triethylamine in an inert organic solvent such as N,N'-dimethylformamide, tetrahydrofuran, a polyhalogenated aliphatic hydrocarbon.
- the reaction temperature is from -2O 0 C to +40°C.
- the reaction is completed
- the compound obtained in the step n) can be nitrated with nitric acid and acetic anhydride according to methods well known in the literature.
- the reaction temperature is from -50 0 C to O 0 C.
- the compounds of formula (Via) are commercially available, or can be synthesized by well known reactions.
- Z-i is a chlorine atom, a bromine atom or a iodine atom with a nitrate source as above described.
- the compounds of formula (VIb) are commercially available or can be synthesized according to methods well known in the literature.
- objects of the present invention are also pharmaceutical compositions containing at least a compound of the present invention of formula (I) together with non toxic adjuvants and/or carriers usually employed in the pharmaceutical field.
- the preferred route of administration is topical.
- the compounds of the present invention can be administered as solutions, suspensions or emulsions (dispersions) in an_ophthalmic acceptable vehicle.
- ophthalmic acceptable vehicle refers to any substance or combination of substances which are non-reactive with the compounds and suitable for administration to patient.
- aqueous vehicles suitable for topical application to the patient's eyes.
- Other ingredients which may be desirable to use in the ophthalmic compositions of the present invention include antimicrobials, preservatives, co-solvents, surfactants and viscosity building agents.
- the invention also relates to a method for treating glaucoma or ocular hypertension, said method consisting in contacting an effective intraocular pressure reducing amount of a composition with the eye in order to reduce eye pressure and to maintain said pressure on a reduced level.
- the doses of prostaglandin nitroderivatives can be determined by standard clinical techniques and are in the same range or less than those described for the corresponding underivatized, commercially available prostaglandin compounds as reported in the: Physician's Desk Reference, Medical Economics Company, Inc., Oradell, N. J., 58 th Ed., 2004; The pharmacological basis of therapeutics, Goodman and Gilman, J. G. Hardman, L. e. Limbird, Tenth Ed.
- compositions contain 0.1-0.30 ⁇ g, especially 1-10 ⁇ g, per application of the active compound.
- the treatment may be advantageously carried out in that one drop of the composition, corresponding to about 30 ⁇ l, is administered about 1 to 2 times per day to the patient's eye.
- the compounds of the present invention can be used with other medicaments known to be useful in the treatment of glaucoma or ocular hypertension, either separately or in combination.
- the compounds of the present invention can be combined with (i) beta-blockers, such as timolol, betaxolol, levobunolol and the like (see U.S. Pat. No. 4,952,581); (ii) carbonic anhydrase inhibitors, such as brinzolamide; (iii) adrenergic agonists including clonidine derivatives, such as apraclonidine or brimonidine (see U.S. Pat. No. 5,811 ,443.
- nitrooxy derivatives of the above reported compounds for example nitrooxy derivatives of beta-blockers such as those described in U.S. Pat. No. 6,242,432.
- Tafluprost acid 115 mg, 0.28 mmol
- 4-bromobutyl nitrate 110.8 mg 18.5% w/w in dichloromethane, 0.56 mmol
- DMF 20 ml
- K 2 CO 3 96.75 mg, 0.7 mmol
- Kl 46.5 mg, 0.28 mmol
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Nitroderivatives of fluoroprostaglandins having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
Description
FLUOROPROSTAGLANDINS NITRQDERIVATIVES
The present invention relates to new flouroprostaglandins nitroderivatives, pharmaceutical compositions containing them and their use as drugs for treating glaucoma and ocular hypertension.
Glaucoma is optic nerve damage, often associated with increased intraocular pressure (lOP), that leads to progressive, irreversible loss of vision.
Almost 3 million people in the United States and 14 million people worldwide have glaucoma; this is the third leading cause of blindness worldwide.
Glaucoma occurs when an imbalance in production and drainage of fluid in the eye (aqueous humor) increases eye pressure to unhealthy levels.
It is known that elevated IOP can be at least partially controlled by administering drugs which either reduce the production of aqueous humor within the eye or increase the fluid drainage, such as beta-blockers, α-agonists, cholinergic agents, carbonic anhydrase inhibitors, or prostaglandin analogs.
Several side effects are associated with the drugs conventionally used to treat glaucoma.
Topical beta-blockers show serious pulmonary side effects, depression, fatigue, confusion, impotence, hair loss, heart failure and bradycardia.
Topical α-agonists have a fairly high incidence of allergic or toxic reactions; topical cholinergic agents (miotics) can cause visual side effects.
The side effects associated with oral carbonic anhydrase inhibitors include fatigue, anorexia, depression, paresthesias and serum electrolyte abnormalities (The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, M. H. Beers and R. Berkow Editors, Sec. 8, Ch. 100).
Finally, the topical prostaglandin analogs (bimatoprost, latanoprost, travoprost and unoprostone) used in the treatment of glaucoma, can produce ocular side effects, such as increased pigmentation of the iris, ocular irritation, conjunctival hyperaemia, iritis, uveitis and macular oedema (Martindale, Thirty-third edition, p. 1445)
U.S. Pat. No. 3,922,293 describes monocarboxyacylates of prostaglandins F-type and their 15β isomers, at the C-9 position, and processes for preparing them; U.S. Pat. No. 6,417,228 discloses 13-aza prostaglandins having functional PGF2α receptor agonist activity and their use in treating glaucoma and ocular hypertension. WO 90/02553 discloses the use of prostaglandins derivatives of PGA, PGB, PGE and PGF, in which the omega chain contains a ring structure, for the treatment of glaucoma or ocular hypertension.
WO 00/51978 describes novel nitrosated and/or nitrosylated prostaglandins, in particular novel derivatives of PGE-i, novel compositions and their use for treating sexual dysfunctions.
U.S. Pat. No. 5,625,083 discloses dinitroglycerol esters of prostaglandins which may be used as vasodilators, antihypertensive cardiovascular agents or bronchodilators.
U.S. Pat. No. 6,211 ,233 discloses compounds of the general formula A-X1-NO2, wherein A contains a prostaglandin residue, in particular PGE1, and X1 is a bivalent connecting bridge, and their use for treating impotence.
U.S. Pat. No. 5,985,920 and U.S. Pat. No. 5,886,035 disclose 15-deoxy-15,15- difluoro-prostaglandins-F2α derivatives and their use in the treatment of glaucoma or ocular hypertension. The results of the pharmacological testes reported in the documents show that these fluoroPGF2α have a long-lasting effect of lowering intraocular pressure and they have a little effect on melanogenesis.
Experimental Eye Research 78 (2004), 767-776 discloses the pharmacological characteristics of tafluprost, which is a 15-deoxy-15,15-difluoro-prostaglandin-F2α derivative. The results of the pharmacological tests demonstrate that tafluprost has a high lOP-reducing efficacy and weak melanogenic side effect.
It is an object of the present invention to provide new derivatives of prostaglandins able not only to eliminate or at least reduce the side effects associated with these compounds, but also to possess an improved pharmacological activity. It has been surprisingly found that fluoroprostaglandins nitroderivatives have an improved lOP-reducing efficacy and an improved overall profile as compared to the known prostaglandin analogs both in terms of broad range of therapeutic applicability for the treatment of eye diseases and of enhanced activity and tolerability. In particular, it has been recognized that the prostaglandin nitroderivatives of the present invention can be employed for treating glaucoma and ocular hypertension. The compounds of the present invention are indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or with chronic angle-closure glaucoma who underwent peripheral iridotomy or laser iridoplasty.
An object of the present invention is, therefore, fluoroprostaglandins nitroderivatives of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof
R-X-(B)m-Y-ONO2
- a aryloxyalkyl group optionally substituted on the aryl moiety with from 1 to 3 halogen atoms or haloalkyl groups; the carbon number of the alkyl moiety of the aryloxyalkyl group (i.e. the alkylene group) is preferably from 1 to 3; the preferred aryloxyalkyl groups are: a phenoxymethyl group, a 3-chlorophenoxymethyl group, a 3-fluorophenoxymethyl group, a 3- (trifluoromethyl) phenoxymethyl group, a 3,5-dichlorophenoxymethyl group, a 3,4- dichlorophenoxymethyl group, a 3,5-difluorophenoxy methyl group, 3,4- difluorophenoxymethyl group, 3,5-bis(trifluoromethyl)phenoxymethyl group and 3,4- bis(trifluoromethyl)phenoxymethyl group;
- a aralkyl group optionally substituted on the aryl moiety with from 1 to 3 halogen atoms or haloalkyl groups or alkoxy groups; the carbon number of the alkyl moiety of the aralky group (i.e. the alkylene group)is preferably from 1 to 4; the preferred aralkyl groups are: a phenylmethyl group, a 2-phenylethyl group, a 3-methylphenylmethyl group, a 2-(3- methylphenyl)ethyl group, 3-(trifluoromethyl) phenylmethyl group, 2-(3- trifluoromethylphenyl)ethyl group, a 3-chlorophenylmethyl group, a 2-(3-chlorophenyl)ethyl group, 2-(3,4-dichlorophenyl)ethyl group or 2-(3,5-dichlorophenyl)ethyl group;
- a C3-C8 alkyl group optionally substituted with halogen atoms, a C1-C4 linear or branched alkyl group, a C5-C6 cycloalkyl group, a C1-C4 alkoxy group, a sulfur atom-containing substituent, a nitrogen atom-containing substituent; preferably R1 is a C5-C6 alkyl group substituted with one or two methyl group and selected from the group comprising: n-pentyl, 2-methylhexyl, 1,1-dimethylpentyl, 2-methypentyl, 2-methylhexyl;
- a C3-C8 alkenyl group optionally substituted with halogen atoms, a C1-C4 linear or branched alkyl group, a C5-C6 cycloalkyl group, a C1-C4 alkoxy group, a sulfur atom-containing substituent, a nitrogen atom-containing substituent; preferably R-i is a C5-C6 alkenyl group substituted with one or two methyl group selected from the group comprising: 1-metyl-3- pentenyl, 1-methyl-3-hexenyl, 1 ,1-dimethyl-3-hexenyl, 2-methyl-3-pentenyl;
a C3-C8 alkynyl group optionally substituted with halogen atoms, a C1-C4 linear or branched alkyl group, a C5-C6 cycloalkyl group, a C1-C4 alkoxy group, a sulfur atom- containing substituent, a nitrogen atom-containing substituent; preferably R1 is a C5- C6 alkynyl group substituted with one or two methyl group selected from the group comprising: 3-pentenyl, 1-methyl-3-hexynyl or 1,1-dimethy-3-hexynyl, 2-metbyl-3- pentenyl; 1-methyl-3-penynyl; 2-methy!-3-hexynyl;
- a C3-C8 cycloalkyl group optionally substituted by a C1-C4 linear or branched alkyl, the preferred C3-C8 cycloalkyl groups are cyclohexyl group or cyclopentyl group; each of R2 and R3 which are independent of one another, is a hydrogen atom or an aliphatic hydrocarbon type C2-C2O acyl group, preferably R2 and R3 are hydrogen atoms; each of R4 and R5 which are independent of one another, is an hydrogen atom or a fluorine atom with the proviso that at least one of R4 and R5 is a fluorine atom, preferably R4 and R5 are fluorine atoms;
X is -O-, -S- or -NR1-, wherein R1 is H or linear or branched C1-C6 alkyl; m is an integer equal to 0 or 1 , with the proviso that m is equal to 0 when X is -O- or -S-; B is a radical of the formula -CH(R1)COO-, wherein R1 is as above defined; Y is a bivalent radical having the following meanings: a) straight or branched C1-C20 alkylene, preferably C1-CiO, being optionally substituted with one or more of the substituents selected from the group consisting of: halogen atoms, hydroxy, -ONO2 or T, wherein T is -OC(O)(C1-C10 alkyl)-ONO2 or -0(C1-C10 alkyl)-ONO2;
C5-C7 cycloalkylene group optionally substituted with linear or branched C1-C10 alkyl group, preferably CH3; b)
c)
wherein n is an integer from 0 to 20, preferably n is an integer from 0 to 5; and n1 is an integer from 1 to 20, preferably n1 is an integer from 1 to 5; d)
wherein
X1 = -OCO- or -COO- and R2 is H or CH3;
Z is -(CH)n 1- or the bivalent radical defined above under b) n1 is as defined above and n2 is an integer from O to 2; e)
Z is -(CH)n 1- or the bivalent radical defined above under b) n1, n2,R2 and Xi are as defined above; with the proviso that: i) when Y is selected from the bivalent radicals mentioned under b)-e), then the -ONO2 group of formula (I) is bound to -(CH2)n 1; ii) when Y is selected from the bivalent radicals mentioned under b) or c), n = O and X is
NR1, wherein R1 is as above defined, then m = 1 ; iii) when Y is selected from the bivalent radicals mentioned under d) or e), X is NR1, wherein R1 is as above defined, then m = 1; f)
wherein: n1 and R2 are as defined above, R3 is H or -COCH3; with the proviso that the -ONO2 group of formula (I) is bound to -(CH2)n 1; and with the proviso that when X is -NR1-, wherein R1 is as above defined Y cannot be f); g)
wherein
X2 js -o- or -S-; n3 is an integer from 1 to 6, preferably from 1 to 4, and R2 is as defined above; h)
R4, R5, R6, R7 are the same or different, and are H or straight or branched C1-C4 alkyl, preferably R4, R5, R6, R7 are H; wherein the -ONO2 group of formula (I) is linked to
Y2 is an heterocyclic saturated, unsaturated or aromatic 5 or 6 members ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulfur, and is selected from
The term "C1-C2O alkylene" as used herein refers to branched or straight C1-C20 hydrocarbon chain, preferably having from 1 to 10 carbon atoms such as methylene, ethylene, propylene, isopropylene, n-butylene, pentylene, n-hexylene and the like.
The term "CrCio alkyl" as used herein refers to branched or straight alkyl groups comprising 1 to 10 carbon atoms, including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, octyl and the like.
The term "cycloalkylene" as used herein refers to ring having from 5 to 7 carbon atoms including, but not limited to, cyclopentylene, cyclohexylene optionally substituted with side chains such as straight or branched (CrC10)-alkyl, preferably CH3.
The term "heterocyclic" as used herein refers to saturated, unsaturated or aromatic 5 or 6 members ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulphur, such as for example pyridine, pyrazine, pyrimidine, pyrrolidine, morpholine, imidazole and the like.
The term "aryloxyalkyl group" as used herein refers to groups wherein the aryl moiety is, for example, a benzene ring, a furan ring, a thiophene ring or a naphthalene ring and may have from 1 to 3 halogen atoms, haloalkyl groups, alkoxy groups or hydroxyl groups as substituents on the aryl moiety. The aryl moiety is preferably a phenyl group which is not substituted or substituted with from 1 to 3 halogen atoms or haloalkyl groups. The carbon number of the alkyl moiety (i.e. the alkylene group) of the aryloxyalkyl group is from 1 to 3. The term "aralkyl" group as used herein refers to groups wherein the aryl moiety is, for example, a benzene ring, a furan ring, a thiophene ring or a naphthalene ring and may be substituted with from 1 to 3 halogen atoms, haloalkyl groups, alkoxy groups or hydroxyl groups. The carbon number of the alkyl moiety substituted with the aryl group is preferably from 1 to 4. As stated above, the invention includes also the pharmaceutically acceptable salts of the compounds of formula (I) and stereoisomers thereof.
Examples of pharmaceutically acceptable salts are either those with inorganic bases, such as sodium, potassium, calcium and aluminium hydroxides, or with organic bases, such as lysine, arginine, triethylamine, dibenzylamine, piperidine and other acceptable organic amines.
The compounds according to the present invention, when they contain in the molecule one salifiable nitrogen atom, can be transformed into the corresponding salts by reaction in an organic solvent such as acetonitrile, tetrahydrofuran with the corresponding organic or inorganic acids. Examples of organic acids are: oxalic, tartaric, maleic, succinic, citric acids. Examples of inorganic acids are: nitric, hydrochloric, sulphuric, phosphoric acids. Salts with nitric acid are preferred.
The compounds of the invention which have one or more asymmetric carbon atoms can exist as optically pure enantiomers, pure diastereomers, enantiomers mixtures, diastereomers mixtures, enantiomer racemic mixtures, racemates or racemate mixtures.
Within the scope of the invention are also all the possible isomers, stereoisomers and their mixtures of the compounds of formula (I), including mixtures enriched in a particular isomer.
Preferred compounds of formula (I) are those wherein_the fluoroprostaglandin precursor is selected from the following moieties R of formula (II) wherein: - the bond between the carbon atoms in positions 13 and 14 is a double bond; R1 is a phenoxymethyl group; R2 and R3 are hydrogen atoms; R4 and R5 are fluorine atoms; or
- the bond between the carbon atoms in positions 13 and 14 is a double bond; Ri is a 3-chlorophenoxymethyl group;
R2 and R3 are hydrogen atoms; R4 and R5 are fluorine atoms; or
- the bond between the carbon atoms in positions 13 and 14 is a single bond; R1 is a phenoxymethyl group; R2 and R3 are hydrogen atoms; R4 and R5 are fluorine atoms; or
- the bond between the carbon atoms in positions 13 and 14 is a single bond; R1 is a 3-chlorophenoxymethyl group;
R2 and R3 are hydrogen atoms; R4 and R5 are fluorine atoms;
X is -O- or -NR1-, wherein R1 is H or C1-C6 alkyl, preferably R1 is H or methyl; m is an integer equal to 0 or 1 , with the proviso that m is equal to 0 when X is -O-; B is a radical of the formula -CH(R1)COO-, wherein R1 is as above defined; Y is a bivalent radical having the following meanings: a) straight or branched C1-C20 alkylene, preferably C1-C10, being optionally substituted by one or more of the substituents selected from the group consisting of: halogen atoms, hydroxy, -ONO2 or T1 wherein T is
-OC(O)(C1-C10 alkyl)-ONO2 or -0(C1-C10 alkyl)-ONO2;
C5-C7 cycloalkylene group optionally substituted with linear or branched C1-C10 alkyl group, preferably CH3; b)
c)
wherein n is an integer from 0 to 20, preferably n is an integer from 0 to 5; and n1 is an integer from 1 to 20, preferably n1 is an integer from 1 to 5; d)
wherein
X1 = -OCO- or -COO- and R2 is H or CH3; Z is -(CH)n 1- or the bivalent radical defined above under b) n1 is as defined above and n2 is an integer from 0 to 2; e)
Z is -(CH)n 1- or the bivalent radical defined above under b) n\ n2,R2 and X1 are as defined above; with the proviso that: i) when Y is selected from the bivalent radicals mentioned under b)-e), then the -ONO2 group of formula (I) is bound to -(CH2)n 1; ii) when Y is selected from the bivalent radicals mentioned under b) or c), n = O and X is NR1, wherein R1 is as above defined, then m = 1 ;
iii) when Y is selected from the bivalent radicals mentioned under d) or e) and X is NR1, wherein R1 is as above defined, then m = 1 ; f)
wherein: n1 and R2 are as defined above, R3 is H or -COCH3; with the proviso that the -ONO2 group of formula (I) is bound to -(CH2)π 1; and with the proviso that when X is -NR1-, wherein R1 is as above defined, Y cannot be f); g)
wherein X2 is -O- or -S-; n3 is an integer from 1 to 6, preferably from 1 to 4, and R2 is as defined above; h)
R4, R5, R6, R7 are the same or different, and are H or straight or branched C1-C4 alky!, preferably R4, R5, R6, R7 are H; wherein the -ONO2 group of formula (I) is linked to
wherein n5 is as defined above;
Y2 is an heterocyclic saturated, unsaturated or aromatic 5 or 6 members ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulfur, and is selected from
The most preferred compounds of formula (I) are those compounds wherein R has the following formula:
X is -O-, S or -NR1-, wherein R1 is H or C1-C6 alkyl, preferably R1 is H or methyl; m is an integer equal to 0 or 1 , with the proviso that m is equal to 0 when X is -O- or S; B is a radical of the formula -CH(R1)COO-, wherein R1 is as above defined; Y is a bivalent radical having the following meanings: a)
- straight or branched C1-Ci0 alkylene, being optionally substituted with -ONO2 or T, wherein T is -OC(O)(C1-C10 alkyl)-ONO2 Or -O(C1-C10 alkyl)-ONO2; b)
c)
wherein n is an integer from O to 20, preferably from 0 to 5; and n1 is an integer from 1 to 20, preferably from 1 to 5; d)
X1 = -OCO- or -COO- and R2 is H or CH3; Z is -(CH)n 1- or the bivalent radical defined above under b) wherein n is an integer from O to 5; n1 is an integer from 1 to 5; and n2 is an integer from O to 2; e)
wherein:
Y1 is -CH2-CH2-(CH2)n 2-; or -CH=CH-(CH2)n 2-; Z is -(CH)n 1- or the bivalent radical defined above under b) with the proviso that: i) when Y is selected from the bivalent radicals mentioned under b)-e), then the -ONO2 group of formula (I) is bound to -(CH2)n 1; ii) when Y is selected from the bivalent radicals mentioned under b) or c), n = 0 and X is
NR1, wherein R1 is as above defined, then m = 1; iii) when Y is selected from the bivalent radicals mentioned under d) or e), X is NR1, wherein R1 is as above defined, then m = 1; f)
wherein: n1 and R2 are as defined above, R3 is H or COCH3; with the proviso that the -ONO2 group of formula (I) is bound to -(CH2)n 1; and with the proviso that when X is -NR1-, wherein R1 is as above defined, Y cannot be f); g)
.3 : n is an integer from 1 to 4; R2 is hydrogen; h)
wherein: n4 is an integer from 0 to 10, preferably from 0 to 3; ns is an integer from 1 to 10, preferably from 1 to 3; R4, R5, R6, R7 are the same and are H; and wherein the -ONO2 group of formula (I) is linked to
Y2 is a 6 member saturated, unsaturated or aromatic heterocyclic ring, containing one or two atoms of nitrogen and selected from
Preferred compounds of the formula (I), according to the present invention, are given below:
The compounds of general formula (I) as above defined, can be obtained: a) by reacting a compound of formula (III)
Ri is as above defined; P is H or a hydroxylic protecting group; W is -OH, Cl, or -OC(O)Ri wherein R1 is a linear or branched C1-C5 alkyl; with a compound of formula (IV) Za-(B)m-Y-Q
(IV) wherein Y ,B and m are as above defined, Za is -OH, -SH, -NHR1 wherein R1 is as above defined,
Q is -ONO2 or Zi wherein Z1 is selected from the group consisting of: a chlorine atom, a bromine atom, a iodine atom, a mesyl group or a tosyl group; in the presence of a condensing agent, and b) when Q is Z1, by converting the compound obtained in the step a) into a nitro derivative by reaction with a nitrate source. c) optionally deprotecting the compounds obtained in step a) or b). Preferred hydroxylic protecting groups are silyl ethers, such as trimethylsilyl, tert-butyl- dimethylsilyl, or acetyl and those described in T. W. Greene "Protective groups in organic synthesis", Harvard University Press, 1980.
Alternately the compound of formula (I) wherein X is -0-, m = O, R and Y are as above defined can be obtained: a.1) by reacting a compound of formula (III) wherein W = -OH, P and L are as above defined, with a compound of formula (IV) wherein Z3 is Z1, m is O, Y and Q are as above defined, in the presence of a organic or inorganic base, and b) when Q is Z1, by converting the compound obtained in the step a.1) into a nitro derivative by reaction with a nitrate source. c) optionally deprotecting the compounds obtained in step a.1) or b).
In step a) the reaction of a compound of formula (111) wherein W = -OH, P and L are as above defined, with a compound of formula (IV) wherein Za, Y, Q, B and m are as above defined, may be carried out in presence of a condensing agent such as N1N'- carbonyldiimidazole (CDI) or dicyclohexylcarbodiimide (DCC), N'-(3-dimethylaminopropyl) - N-ethylcarbodiimide hydrochlo ride (EDAC) and a catalyst, such as N,N-dimethylamino pyridine (DMAP). The reaction is carried out in a dry inert organic solvent such as N1N'- dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon. The reaction temperature is from -200C to +4O0C. The reaction is completed within a time range from 30 minutes to 36 hours. In step a) the reaction of a compound of formula (III) wherein W = -OC(O)R1 wherein R-i and P are as above defined, with a compound of formula (IV) wherein Z3, Y, B and m are as above defined and Q is -ONO2, may be carried out in presence of a catalyst, such as N1N- dimethylamino pyridine (DMAP). The reaction is carried out in an inert organic solvent such as N.N'-dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated
aliphatic hydrocarbon. The reaction temperature is from -20°C to +4O°C. The reaction is completed within a time range from 30 minutes to 36 hours.
In step a) the reaction of a compound of formula (III) wherein W = Cl and P is as above defined, with a compound of formula (IV) wherein Za, Y, B and m are as above defined and Q is -ONO2, may be carried out in presence of a organic base such as N,N-dimethylamino pyridine (DMAP), triethylamine, pyridine. The reaction is carried out in an inert organic solvent such as N,N'-dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon. The reaction temperature is from -2O0C to 4O0C. The reaction is completed within a time range from 30 minutes to 36 hours. In step a.1) The preferred organic bases are for example 1 ,8-diazabiciclo[5.4.0]undec-7-ene (DBU), N,N-diisopropyl ethylamine, diisopropylamine; preferred inorganic base are alkaline- earth metal carbonate or hydroxide, potassium carbonate, cesium carbonate. The reaction is carried out in an inert organic solvent such as N,N'-dimethylformamide, tetrahydrofuran, acetone, methyl ethyl ketone, acetonitrile, a polyhalogenated aliphatic hydrocarbon. The reaction temperature is from -20°C to +40°C, preferably from 50C to 25°C. The reaction is completed within a time range from 1 to 8 hours. When Z1 is a chlorine atom or a bromine atom the reaction is carried out in presence an iodine compound such as Kl. In the step b) the nitrate source may be silver nitrate, lithium nitrate, sodium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, iron nitrate, zinc nitrate or tetraalkylammonium nitrate (wherein alkyl is C1-C10 alkyl). The reaction is carried out in the dark and in a suitable organic solvent such as acetonitrile, tetrahydrofurane, methyl ethyl ketone, ethyl acetate, DMF. The reaction temperature is from room temperature to the boiling temperature of the solvent. Preferred nitrate source is silver nitrate. Step c) the protected hydroxyl groups can be converted to hydroxyl groups by methods described in T. W. Greene "Protective groups in organic synthesis", Harvard University Press, 1980. Fluoride ion is the preferred method for removing silyl ether protecting group.
The compounds of formula (III) wherein W = -OH and P = H may be synthesized as described in US patent N° 5,985,920. The synthesis of the (16-phenoxy-15-deoxy-15,15- difluoro-PGF2α) 16-phenoxy-15-deoxy-15, 15-difluoro-17,18, 19,20-tetranorprostaglandin-F2α is also described in Tetrahedron Letters 45 (2004), 1527-1529.
The compounds of formula (III) wherein W = -OH and P is a hydroxylic protecting group may be prepared from the corresponding compounds wherein P = H as well known in the art, for example as described in T. W. Greene "Protective groups in organic synthesis", Harvard University Press, 1980. The compounds of formula (III) wherein W = -OC(O)Ri and P is as above defined may be obtained from the corresponding acids wherein W = -OH by reaction with a chloroformate such as isobutylchloroformate, ethylchloroformate in presence of a non- nucleophilic base such as triethylamine in an inert organic solvent such as N1N'- dimethylformamide, tetrahydrofuran, a polyhalogenated aliphatic hydrocarbon at a
temperature from -20°C and 40°C. The reaction is completed within a time range from 1 to 8 hours.
The compounds of formula (III) wherein W = Cl may be obtained from the corresponding acids wherein W = -OH by reaction with a thionyl or oxalyl chloride, halides of P1" or Pv in solvents inert such as toluene, chloroform, DMF.
The compounds of formula (IV) Za-(B)m-Y-Q, wherein Za is -NHR1, m=0, Q is -ONO2, R1 and Y are as above defined can be obtained: e) by reacting a compound of formula (IVa)
R1NH-Y-Z1
(IVa) wherein R1, Y and Z1 are as above defined, in the presence of a nitrate source.
The nitrate source may be silver nitrate, lithium nitrate, sodium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, iron nitrate, zinc nitrate or tetraalkylammonium nitrate (wherein alkyl is C1-C10 alkyl). Preferred nitrate source is silver nitrate. The reaction is carried out in the dark and in a suitable organic solvent such as acetonitrile, tetrahydrofurane, methyl ethyl ketone, ethyl acetate, DMF. The reaction temperature is from room temperature to the boiling temperature of the solvent.
The compound of formula (IVa) wherein R1, Y and Z-i are as above defined, can be synthesized f) by reacting a compound of formula (IVa')
R1NH-Y-OH
(IVa') wherein R1, and Y are as above defined, with thionyl or oxalyl chloride, halides of P'" or Pv , mesyi chloride, tosyl chloride in solvents inert such as toluene, chloroform, DMF, etc., according to well known methods.
The compounds of formula (IVa') wherein R1, and Y are as above defined, are commercially available or can be synthesized by process well known in the art.
Alternatively, the compounds of formula (IV) Za-(B)m-Y-Q, wherein Za is -NHR1, m=0, Q is -ONO2, R1 and Y are as above defined can be obtained by reacting the aminoalcohol of formula (IVa') with nitric acid and acetic anhydride according to methods well known in the literature. The reaction temperature is usually from -5O0C to 0°C.
The compounds of formula (IV) Za-(B)m-Y-Q, wherein Za is -OH or -SH, m=0, Q is - ONO2 and Y are as above defined can be obtained: g) by reacting a compound of formula (IVb)
Za-Y-Z1 (IVb) wherein Za, Y and Z1 are as above defined, in the presence of a nitrate source. The nitrate source may be silver nitrate, lithium nitrate, sodium nitrate, potassium nitrate, magnesium nitrate, calcium nitrate, iron nitrate, zinc nitrate or tetraalkylammonium nitrate
(wherein alky! is C1-C10 alkyl). Preferred nitrate source is silver nitrate. The reaction is carried out in the dark and in a suitable organic solvent such as acetonitrile, tetrahydrofurane, methyl ethyl ketone, ethyl acetate, DMF. The reaction temperature is from room temperature to the boiling temperature of the solvent. The compound of formula (IVb) wherein Za, Y and 2i are as above defined, can be synthesized h) by reacting a compound of formula (IVb')
Za-Y-OH
(IVb') wherein Za and Y are as above defined, with thionyl or oxalyl chloride, halides of P'" or Pv , mesyl chloride, tosyl chloride in solvents inert such as toluene, chloroform, DMF, etc., according to well known methods.
The compounds of formula (IVb') wherein Za and Y are as above defined, are commercially available or can be synthesized by processes well known in the art. Alternatively, the compounds of formula (IV) Za-(B)111-Y-Q, wherein Za is -OH, m=0, Q is -ONO2 and Y is as above defined, can be obtained by reacting a diol derivative of formula (IVb") HO-Y-OH with nitric acid and acetic anhydride according to methods well known in the literature. The reaction temperature is usually from -500C to O0C.
The compounds of formula (IV) Za-(B)m-Y-Q, wherein Za is -NHR1, m=1, Q, Y, and B are as above defined, and can be obtained by reacting i) a compound of formula (V)
P.,NR1-CH(R1)C(O)-W,
(V) wherein W is -OH, Cl, or -OC(O)R1 wherein R1 is a linear or branched C1-C5 alkyl, R1 is as above defined, P1 is H or a amino protecting group, with a compound of formula (Vl)
Z3-Y-Q (Vl) wherein Z3 is HO or Z1, Y Q and Z1 are as above defined, and
I) when Q is Z1, by converting the compound obtained in the step i) to the nitro derivative as above described. m) optionally deprotecting the compounds obtained in step i) or I).
Preferred protecting groups for a amino group are for example tert-butylcarbamate (BOC), such as 2,2,2-trichloroethyl carbamate (TROC) and those described in T. W. Greene
"Protective groups in organic synthesis", Harvard University Press, 1980, The protecting groups for a amino group can be converted to a amino group by conventional methods, for example, as described in T. VV. Greene "Protective groups in organic synthesis", Harvard University Press, 1980;
In step i) the reaction of a compound of formula (V) wherein W = -OH, with a compound of formula (Vl) wherein Z3 HO, Y and Q are as above defined, may be carried out in presence of a dehydrating agent as dicyclohexylcarbodiimide (DCC) or N'-(3-dimethylaminopropyl)-N-
ethylcarbodiimide hydrochloride (EDAC) and a catalyst, such as N,N-dimethylamino pyridine (DMAP). The reaction is carried out in a dry inert organic solvent such as N1N'- dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon. The reaction temperature is from -200C to +400C. The reaction is completed within a time range from 30 minutes to 36 hours.
In step i) the reaction of a compound of formula (V) wherein W = -OC(O)R1 wherein R1 is as above defined, with a compound of formula (Vl) wherein Z3 is -OH, Q is -ONO2 and Y is as above defined, may be carried out in presence of a catalyst, such as N,N-dimethylamino pyridine (DMAP). The reaction is carried out in an inert organic solvent such as N1N'- dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon. The reaction temperature is from -2O0C to +400C. The reaction is completed within a time range from 30 minutes to 36 hours.
In step i) the reaction of a compound of formula (V) wherein W = -OH, with a compound of formula (Vl) wherein Z3 is Z1, Q is -ONO2, Z1 and Y are as above defined, may be carried out in presence of a organic base such as 1,8-diazabiciclo[5.4.0]undec-7-ene (DBU), N1N- diisopropylethyl amine, diisopropylamine or inorganic base such as alkaline-earth metal carbonate or hydroxide, potassium carbonate, cesium carbonate, in an inert organic solvent such as N,N'-dimethylformamide, tetrahydrofuran, acetone, methyl ethyl ketone, acetonitrile, a polyhalogenated aliphatic hydrocarbon. The reaction temperature is from -2O0C to +40°C, preferably from 5°C to +25°C. The reaction is completed within a time range from 1 to 8 hours.
When Z1 is a chlorine atom or a bromine atom the reaction is carried out in presence an iodine compound such as Kl. The reaction of a compound of formula (V) wherein W = Cl and P-i is as above defined, with a compound of formula HO-Y-Q wherein Q is -ONO2 and Y is as above defined, may be carried out in presence of a organic base such as N,N-dimethylamino pyridine (DMAP), triethylamine, pyridine. The reaction is carried out in an inert organic solvent such as N1N'- dimethylformamide, tetrahydrofuran, benzene, toluene, dioxane, a polyhalogenated aliphatic hydrocarbon. The reaction temperature is from -200C to +4O0C. The reaction is completed within a time range from 30 minutes to 36 hours.
The compounds of formula (V) wherein W = -OC(O)Ri and P-i = H may be obtained from the corresponding acids wherein W = -OH by reaction with a chloroformate such as isobutylchloroformate, ethylchloroformate in presence of a non-nucleophilic base such as triethylamine in an inert organic solvent such as N,N'-dimethylformamide, tetrahydrofuran, a polyhalogenated aliphatic hydrocarbon. The reaction temperature is from -2O0C to +40°C. The reaction is completed within a time range from 1 to 8 hours.
The compounds of formula (V) wherein W = Cl may be obtained from the corresponding acids wherein W = -OH by reaction with a thionyl or oxalyl chloride, halides of P'" or Pv in solvents inert such as toluene, chloroform, DMF.
The compounds of formula (V) wherein W = -OH are commercially available or can be synthesized according to methods well known in the literature
The compounds of formula (Vl) Z3-Y-Q wherein Z3 is -OH, Q is -ONO2 and Y is as above defined can be obtained: n) by reacting a compound of formula (Via)
HO-Y-OH
(Via) wherein Y is as above defined, with thionyl or oxalyl chloride, halides of P1" or Pv , mesyl chloride, tosyl chloride in solvents inert such as toluene, chloroform, DMF, etc. o) by converting the compound obtained in the step n) to the mono nitro derivative by reaction with a nitrate source as above described.
Alternatively the compound obtained in the step n) can be nitrated with nitric acid and acetic anhydride according to methods well known in the literature. The reaction temperature is from -500C to O0C. The compounds of formula (Via) are commercially available, or can be synthesized by well known reactions.
The compounds of formula (Vl) Z3-Y-Q wherein Q is -ONO2, Z3 is Z1, Y and Z1 are as above defined can be obtained by reacting a compound of formula (VIb)
Z1-Y-Z1 (VIb) wherein Z-i is a chlorine atom, a bromine atom or a iodine atom with a nitrate source as above described.
The compounds of formula (VIb) are commercially available or can be synthesized according to methods well known in the literature. As mentioned above, objects of the present invention are also pharmaceutical compositions containing at least a compound of the present invention of formula (I) together with non toxic adjuvants and/or carriers usually employed in the pharmaceutical field.
The preferred route of administration is topical.
The compounds of the present invention can be administered as solutions, suspensions or emulsions (dispersions) in an_ophthalmic acceptable vehicle. The term "ophthalmic acceptable vehicle" as used herein refers to any substance or combination of substances which are non-reactive with the compounds and suitable for administration to patient.
Preferred are aqueous vehicles suitable for topical application to the patient's eyes. Other ingredients which may be desirable to use in the ophthalmic compositions of the present invention include antimicrobials, preservatives, co-solvents, surfactants and viscosity building agents.
The invention also relates to a method for treating glaucoma or ocular hypertension, said method consisting in contacting an effective intraocular pressure reducing amount of a composition with the eye in order to reduce eye pressure and to maintain said pressure on a reduced level.
The doses of prostaglandin nitroderivatives can be determined by standard clinical techniques and are in the same range or less than those described for the corresponding underivatized, commercially available prostaglandin compounds as reported in the: Physician's Desk Reference, Medical Economics Company, Inc., Oradell, N. J., 58th Ed., 2004; The pharmacological basis of therapeutics, Goodman and Gilman, J. G. Hardman, L. e. Limbird, Tenth Ed.
The compositions contain 0.1-0.30 μg, especially 1-10 μg, per application of the active compound.
The treatment may be advantageously carried out in that one drop of the composition, corresponding to about 30 μl, is administered about 1 to 2 times per day to the patient's eye.
It is further contemplated that the compounds of the present invention can be used with other medicaments known to be useful in the treatment of glaucoma or ocular hypertension, either separately or in combination. For example the compounds of the present invention can be combined with (i) beta-blockers, such as timolol, betaxolol, levobunolol and the like (see U.S. Pat. No. 4,952,581); (ii) carbonic anhydrase inhibitors, such as brinzolamide; (iii) adrenergic agonists including clonidine derivatives, such as apraclonidine or brimonidine (see U.S. Pat. No. 5,811 ,443. Also contemplated is the combination with nitrooxy derivatives of the above reported compounds, for example nitrooxy derivatives of beta-blockers such as those described in U.S. Pat. No. 6,242,432.
The following examples are to further illustrate the invention without limiting it.
Example 1 Synthesis of 15,15-difluoro-9α, 11α-dihydroxy-16-phenoxy-17,18,19,20-tetranor-pregna-5Z, 13E-dien-1-oic acid 4-(nitrooxy)butyl ester (corresponding to compound of formula 43)
1.1 Preparation of 4-bromobutanol Tetrahydrofurane (12.5 g, 173 mmol) are charged under nitrogen in a reactor cooled to 5- 10°C. Hydrogen bromide (7.0 g, 86.5 mmol) is then added slowly and the reaction medium is stirred over a period of 4.5 hours at 5-100C. The mixture is diluted with 22.5 g of cold water and the pH of this solution adjusted to pH= 5-7 by adding 27.65% sodium Hydroxide (2.0 g) keeping the temperature at 5-1O0C. The solution is then extracted twice with dichloromethane (13.25 g). The combined organic phases are washed with 25% brine (7.5 g), adjusted to pH = 6-7 with 27.65% sodium hydroxide and dried over magnesium sulphate. Dichloromethane is distilled off and crude 4-bromobutanol (10.3 g, 66.9 mmol) is obtained in a yield of about 77%.
1.2 Preparation of 4-bromobutyl nitrate
In a reactor cooled to -5 to 5°C, nitric acid fuming (8.5 g, 135 mmol) is slowly added to a solution of 98% sulphuric acid (13.0 g, 130 mmol) in dichloromethane (18 g, 212 mmol). 4- Bromobutanol (10.2 g, 66.6 mmol) is then added to 50C over a period of 2-5 hours. The mixture is poured onto cold water (110 g) keeping the temperature between -50C and 3°C. After decantation, the upper aqueous phase is extracted with dichloromethane and the combined organic phases are washed with water, adjusted to pH= 6-7 by addition of 27.65% sodium hydroxide, washed with brine and dried over magnesium sulphate. Dichloromethane is distilled off under vacuum and crude 4-bromobutyl nitrate (12.7 g, 64.1 mmol) is recovered in a yield of about 96%.
1.3 Preparation of 15,15-difluoro-9α, 11α-dihydroxy-16- phenoxy-17,18,19,20-tetranor-pregna-5Z, 13E-dien-1- oic acid 4-(nitrooxy)butyl ester
Tafluprost acid (115 mg, 0.28 mmol) and 4-bromobutyl nitrate (110.8 mg 18.5% w/w in dichloromethane, 0.56 mmol) were dissolved in DMF (20 ml). K2CO3 (96.75 mg, 0.7 mmol) and Kl (46.5 mg, 0.28 mmol) were added. The reaction was stirred at room temperature for
12 hours. The reaction mixture was diluted with ethyl acetate (20 ml), washed with water (2x
20 ml), dried over sodium sulphate and evaporated under vacuum. The crude product was purified by flash chromatography, eluent n-hexane/ethyl acetate 4.5/5.5. The product (50 mg) was obtained as oil.
1H-NMR (CDCI3) δ: 7.32 (3H, m); 7.00 (1H, t); 6.93 (2H, d); 6.11 (1 H, m); 5.78 (1 H, m); 5.40 (2H, m); 4.45 (2H, t); 4.22-4.02 (6H, m); 2.50-2.25 (7H, m); 2.25-1.98 (5H, m); 1.9-1.55 (5H, m).
Example 2
Synthesis of 15, 15-difluoro-9α, 11 α-dihydroxy-16-phenoxy-17,18,19,20-tetranor-pregna-5Z, 13E-dien-1-oic acid [2-methoxy-4-[2-propenoyloxy(4-nitrooxybutyl)]]phenyl ester (corresponding to compound of formula 53)
2.1 Preparation of ferulic acid 4-(bromo)butyl ester
To a solution of ferulic acid (1g, 5.15mmol) in tetrahydrofurane (40ml), triphenylphosphine (2.7g, 10.3mmol) and tetrabromomethane (3.41g, 10.3mmol) were added. The mixture was stirred at room temperature for 4 hours. The mixture was filtered and the solvent was evaporated under vacuum. The crude residue was purified by silica gel chromatography,
eluent n-hexane/ethyl acetate 7/3. The product (0.77g) was obtained as a yellow solid. (Yield 46%) M.p.=83-88°C
2.2 Preparation of ferulic acid 4-(nitrooxy)butyl ester
A solution of compound 2.1 (0.8g, 2.43mmol) and silver nitrate (1.2g, 7.29mmol) in acetonitrile (50ml) was stirred at 40°C, in the dark, for 16 hours. The precipitated (silver salts) was filtered off and the solvent was evaporated under vacuum. The residue was purified by flash chromatography, eluent n-hexane/ethyl acetate 75/25. The product (0.4g) was obtained as white powder (yield 53%) M.p.=63-64°C
2.3 Preparation of 15,15-difluoro-9α, 11α-dihydroxy-16-phenoxy-17,18,19,20- tetranor-pregna-5Z, 13E-dien-1~oic acid [2-methoxy-4-[2-propenoyloxy(4- nitrooxybutyl)]] phenyl ester
To a solution of tafluprost acid (0,2g, 0.487mmol) in chloroform (40ml), ferulic acid 4- (nitrooxy)butyl ester (0,23g, 0.73mmol) and DMAP (cat. amount) were added. The reaction was cooled at O°C and EDAC (0.14g, 0.76mmol) was added. The reaction was stirred at room temperature for 24 hours. The solution was treated with water and chloroform, the organic layers were anidrified with sodium sulfate and concentrated under reduced pressure. The residue was purified by flash chromatography, eluent n-hexane/ethyl acetate 45/55. The product (0,1g) was obtained.
1H-NMR (CDCI3) δ: 7.63 (1H, d); 7.32-7.27 (3H, m); 7.14-6.89 (7H, m); 6.37 (1H, d); 6.11 (1H, m); 5.82 (1 H, m); 5.44 (2H, m); 4.52 (2H, t); 4.27-4.15 (6H, m); 3.90 (3H, s); 2.70-1.90 (14H, m).
Claims
Claims A compound of formula (I) and pharmaceutically acceptable salts or stereoisomers thereof
R-X-(B)m-Y-ONO2
(D wherein R is the prostaglandin residue of formula (II):
R1 is selected from:
- a aryloxyalkyl group optionally substituted on the aryl moiety with from 1 to 3 halogen atoms or haloalkyl groups; - a aralkyl group optionally substituted on the aryl moiety with from 1 to 3 halogen atoms or haloalkyl groups or alkoxy groups;
- a C3-C8 alkyl group optionally substituted with halogen atoms, a C1-C4 linear or branched alkyl group, a C5-C6 cycloalkyl group, a C1-C4 alkoxy group, a sulfur atom- containing substituent, a nitrogen atom-containing substituent;
- a C3-C8 alkenyl group optionally substituted with halogen atoms, a C1-C4 linear or branched alkyl group, a C5-C6 cycloalkyl group, a C1-C4 alkoxy group, a sulfur atom- containing substituent, a nitrogen atom-containing substituent;
- a C3-C8 alkynyl group optionally substituted with halogen atoms, a C1-C4 linear or branched alkyl group, a C5-C6 cycloalkyl group, a C1-C4 alkoxy group, a sulfur atom- containing substituent, a nitrogen atom-containing substituent;
- a C3-C8 cycloalkyl group optionally substituted by a C1-C4 linear or branched alkyl, the preferred C3-C8 cycloalkyl groups are cyclohexyl group or cyclopentyl group; each of R2 and R3 which are independent of one another, is a hydrogen atom or an aliphatic hydrocarbon type C2-C2O acyl group; each of R4 and R5 which are independent of one another, is an hydrogen atom or a fluorine atom with the proviso that at least one of R4 and R5 is a fluorine atom, preferably R4 and R5 are fluorine atoms;
X is -O-, -S- or -NR1-, wherein R1 is H or linear or branched C1-C6 alkyl; m is an integer equal to 0 or 1 , with the proviso that m is equal to 0 when X is -O- or -
S-;
B is a radical of the formula -CH(R1)COO-, wherein R1 is as above defined;
Y is a bivalent radical having the following meanings: a) - straight or branched C1-C20 alkylene, preferably C1-C10, being optionally substituted with one or more of the substituents selected from the group consisting of: halogen atoms, hydroxy, -ONO2 or T, wherein T is -OC(O)(C1-C10 alkyl)-ONO2 or -0(C1-C10 alkyl)-ONO2;
- C5-C7 cycloalkylene group optionally substituted with linear or branched C1-C10 alkyl group, preferably CH3; b)
c) wherein n is an integer from 0 to 20, preferably n is an integer from 0 to 5; and n1 is an integer from 1 to 20, preferably n1 is an integer from 1 to 5; d)
wherein
X1 = -OCO- or -COO- and R2 is H or CH3; Z is -(CH)n 1- or the bivalent radical defined above under b) n1 is as defined above and n2 is an integer from 0 to 2; e)
Y1 is -CH2-CH2-(CH2)n 2-; or -CH=CH-(CH2)n2-; Z is -(CH)n 1- or the bivalent radical defined above under b) n1, n2,R2 and X1 are as defined above; with the proviso that: iv) when Y is selected from the bivalent radicals mentioned under b)-e), then the -ONO2 group of formula (I) is bound to -(CH2)n 1; v)when Y is selected from the bivalent radicals mentioned under b) or c), n = 0 and X is NR1, wherein R1 is as above defined, then m = 1 ; vi) when Y is selected from the bivalent radicals mentioned under d) or e) and
X is NR1, wherein R1 is as above defined, then m = 1 ; f)
wherein: n1 and R2 are as defined above, R3 is H or -COCH3; with the proviso that the -ONO2 group of formula (I) is bound to -(CH2)n 1; and with the proviso that when X is -NR1-, wherein R1 is as above defined Y cannot be f); g)
wherein
X2 is -O- or -S-; n3 is an integer from 1 to 6, preferably from 1 to 4, and R2 is as defined above; h)
R4, R5, R6, R7 are the same or different, and are H or straight or branched C1-C4 alkyl, preferably R4, R5, R6, R7 are H; wherein the -ONO2 group of formula (I) is linked to
Y2 is an heterocyclic saturated, unsaturated or aromatic 5 or 6 members ring, containing one or more heteroatoms selected from nitrogen, oxygen, sulfur, and is selected from
2. A compound of formula (I) according to claim 1 wherein Ri is: a phenoxymethyl group, a 3-chlorophenoxymethyl group, a 3-fluorophenoxymethyl group, a 3-(trifluoromethyl) phenoxymethyl group, a 3 , 5- dichiorophenoxymethyl group, a 3,4-dichlorophenoxymethyl group, a 3,5- difluorophenoxy methyl group, 3,4-difluorophenoxymethyl group, 3,5- bis(trifluoromethyl)phenoxymethyl group, 3,4-bis(trifluoromethyl)phenoxymethyl group; a phenylmethyl group, a 2-phenylethyl group, a 3-methylphenylmethyl group, a 2-(3- methylphenyl)ethyl group, 3-(trifluoromethy!) phenylmethyl group, 2-(3- trifluoromethylphenyl)ethyl group, a 3-chlorophenylmethyl group, a 2-(3- chlorophenyl)ethyl group, 2-(3,4-dichlorophenyl)ethyl group, 2-(3,5- dichlorophenyl)ethyl group; n-pentyl, 2-methylhexyl, 1,1-dimethylpentyl, 2-methypentyl, 2-methylhexyl;
1-metyl-3-pentenyl, 1-methyl-3-hexenyl, 1 ,1-dimethyl-3-hexenyl, 2-methyl-3-pentenyl; 3-pentenyl, 1-methyl-3-hexynyl or 1 ,1-dimethy-3-hexynyl, 2-methyl-3-pentenyl; 1- methyl-3-penynyl; 2-methyl-3-hexynyl; a cyclohexyl group or a cyclopentyl group.
3. A compound of formula (I) according to claim 1 or 2 wherein R2 and R3 are hydrogen atoms.
4. A compound of formula (I) according to claims 1-3 wherein R4 and R5 are fluorine atoms;
5. A compound of formula (I) according to claim 1 wherein in the fluoroprostaglandin precursor of formula (II):
- the bond between the carbon atoms in positions 13 and 14 is a double bond; R1 is a phenoxymethyl group;
R2 and R3 are hydrogen atoms; R4 and R5 are fluorine atoms; or
- the bond between the carbon atoms in positions 13 and 14 is a double bond;
6. A compound of formula (I) according to claim 1 wherein in the fluoroprostaglandin precursor of formula (II):
R1 is a 3-chlorophenoxymethyl group; R2 and R3 are hydrogen atoms; R4 and R5 are fluorine atoms; or
- the bond between the carbon atoms in positions 13 and 14 is a single bond;
7. A compound of formula (I) according to claim 1 wherein in the fluoroprostaglandin precursor of formula (II):
R1 is a phenoxymethyl group; R2 and R3 are hydrogen atoms;
R4 and R5 are fluorine atoms;
8. A compound of formula (I) according to claim 1 wherein in the fluoroprostaglandin precursor of formula (II):
- the bond between the carbon atoms in positions 13 and 14 is a single bond; Ri is a 3-chlorophenoxymethyl group;
R2 and R3 are hydrogen atoms;
9. A compound of formula (I) according to claim 1 wherein R has the following formula:
X is -O-, S or -NR1-, wherein R1 is H or C1-C6 alkyl, preferably R1 is H or methyl; m is an integer equal to 0 or 1 , with the proviso that m is equal to 0 when X is -O- or
S;
B is a radical of the formula -CH(R1)COO-, wherein R1 is as above defined; Y is a bivalent radical having the following meanings: a) - straight or branched C1- 10 alkylene, being optionally substituted with -ONO2 or T, wherein T is -OC(O)(C1-C10 alkyl)-ONO2 or -0(C1-C10 alkyl)-ONO2; b)
wherein n is an integer from 0 to 20, preferably from 0 to 5; and n1 is an integer from 1 to 20, preferably from 1 to 5; d)
X1 = -OCO- or -COO- and R2 is H or CH3;
Z is -(CH)n 1- or the bivalent radical defined above under b) wherein n is an integer from 0 to 5; n1 is an integer from 1 to 5; and n2 is an integer from 0 to 2; e)
Z is -(CH)n 1- or the bivalent radical defined above under b) with the proviso that: i) when Y is selected from the bivalent radicals mentioned under b)-e), then the -
ONO2 group of formula (I) is bound to -(CH2)n 1; iv) when Y is selected from the bivalent radicals mentioned under b) or c), n = O and X is NR1, wherein R1 is as above defined, then m = 1 ; v)when Y is selected from the bivalent radicals mentioned under d) or e), X is NR1, wherein R1 is as above defined, then m = 1 ; f)
wherein: n1 and R2 are as defined above, R3 is H or COCH3; with the proviso that the -ONO2 group of formula (I) is bound to -(CH2)n 1; and with the proviso that when X is -NR1-, wherein R1 is as above defined, Y cannot be f); g)
wherein: n4 is an integer from 0 to 10, preferably from 0 to 3; n5 is an integer from 1 to 10, preferably from 1 to 3;
R4, R5, R6, R7 are the same and are H; and wherein the -ONO2 group of formula (I) is linked to
Y2 is a 6 member saturated, unsaturated or aromatic heterocyclic ring, containing one or two atoms of nitrogen and selected from
10. A compound selected from the following group: [I) )
(3) :
11. A compound of general formula (I) according to claims 1-10 for use as a medicament.
12. Use of a compound according to claims 1-10 for the preparation of a medicament for treating glaucoma and ocular hypertension.
13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of general formula (I) and/or a salt or stereoisomer thereof as defined in claims 1-10.
14. A pharmaceutical composition according to claim 13 in a suitable form for the topical administration.
15. A pharmaceutical composition according to claims 13-14 for the treatment of glaucoma and ocular hypertension.
16. A pharmaceutical composition according to claims 13-14, wherein the compound of general formula (I) is administered as a solution, suspension or emulsion in an ophthalmic acceptable vehicle.
17. A method for treating glaucoma or ocular hypertension, said method consisting in contacting an effective intraocular pressure reducing amount of a pharmaceutical composition according to claims 13-14, with the eye in order to reduce eye pressure and to maintain said pressure on a reduced level.
18. A pharmaceutical composition comprising a mixture of a compound of formula (I) as defined in claim 1 and (i) a beta-blocker or (ii) a carbonic anhydrase inhibitor or (iii) an adrenergic agonist or a nitrooxy derivative thereof.
19. A pharmaceutical composition comprising a mixture of a compound of formula (I) as defined in claim 1 and timolol or a nitrooxy derivative thereof.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002613010A CA2613010A1 (en) | 2005-06-29 | 2006-06-19 | Fluoroprostaglandins nitroderivatives |
JP2008518997A JP2009500315A (en) | 2005-06-29 | 2006-06-19 | Nitro derivatives of fluoroprostaglandins. |
EP06765591A EP1917239A1 (en) | 2005-06-29 | 2006-06-19 | Fluoroprostaglandins nitroderivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69635405P | 2005-06-29 | 2005-06-29 | |
US60/696,354 | 2005-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007000642A1 true WO2007000642A1 (en) | 2007-01-04 |
Family
ID=36926812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2006/001728 WO2007000642A1 (en) | 2005-06-29 | 2006-06-19 | Fluoroprostaglandins nitroderivatives |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1917239A1 (en) |
JP (1) | JP2009500315A (en) |
CA (1) | CA2613010A1 (en) |
WO (1) | WO2007000642A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011057386A1 (en) * | 2009-11-13 | 2011-05-19 | Oral Delivery Technology Ltd. | Composition and prophylactic device for enhancing sexual performance or pleasure |
WO2012018324A1 (en) * | 2010-08-02 | 2012-02-09 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
CN102675404A (en) * | 2012-05-10 | 2012-09-19 | 福建天泉药业股份有限公司 | Preparation method of glycyrrhetinic acid butyl nitrate |
US8361994B2 (en) | 2011-03-07 | 2013-01-29 | Merck Sharp & Dohme Corp | Primary amine diazeniumdiolate heterocyclic derivatives |
US9006291B2 (en) | 2009-02-03 | 2015-04-14 | Pharma Patent Holding Inc. | Composition, method and kit for enhancing hair |
WO2016156104A1 (en) | 2015-03-31 | 2016-10-06 | Nicox S.A. | Nitric oxide donating derivatives of latanoprost free acid |
EP3088388A1 (en) | 2015-04-30 | 2016-11-02 | NicOx S.A. | Nitric oxide donating derivatives of prostaglandins |
US9808531B2 (en) | 2015-09-22 | 2017-11-07 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
WO2018087092A1 (en) | 2016-11-08 | 2018-05-17 | Bausch & Lomb Incorporated | Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma |
US10280138B2 (en) | 2015-03-31 | 2019-05-07 | Nicox S.A. | Nitric oxide donating derivatives of fluprostenol |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9115109B2 (en) * | 2013-08-15 | 2015-08-25 | Chirogate International Inc. | Processes and intermediates for the preparations of isomer free prostaglandins |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5625083A (en) * | 1995-06-02 | 1997-04-29 | Bezuglov; Vladimir V. | Dinitroglycerol esters of unsaturated fatty acids and prostaglandins |
US5985920A (en) * | 1996-12-26 | 1999-11-16 | Asahi Glass Company Ltd. | Difluoroprostaglandin derivatives and their use |
US6211233B1 (en) * | 1997-06-19 | 2001-04-03 | Nicox S.A. | Prostaglandin pharmaceutical compositions |
WO2005068421A1 (en) * | 2004-01-05 | 2005-07-28 | Nicox, S.A. | Prostaglandin nitrooxyderivatives |
-
2006
- 2006-06-19 JP JP2008518997A patent/JP2009500315A/en not_active Withdrawn
- 2006-06-19 WO PCT/IB2006/001728 patent/WO2007000642A1/en active Application Filing
- 2006-06-19 CA CA002613010A patent/CA2613010A1/en not_active Abandoned
- 2006-06-19 EP EP06765591A patent/EP1917239A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5625083A (en) * | 1995-06-02 | 1997-04-29 | Bezuglov; Vladimir V. | Dinitroglycerol esters of unsaturated fatty acids and prostaglandins |
US5985920A (en) * | 1996-12-26 | 1999-11-16 | Asahi Glass Company Ltd. | Difluoroprostaglandin derivatives and their use |
US6211233B1 (en) * | 1997-06-19 | 2001-04-03 | Nicox S.A. | Prostaglandin pharmaceutical compositions |
WO2005068421A1 (en) * | 2004-01-05 | 2005-07-28 | Nicox, S.A. | Prostaglandin nitrooxyderivatives |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006291B2 (en) | 2009-02-03 | 2015-04-14 | Pharma Patent Holding Inc. | Composition, method and kit for enhancing hair |
WO2011057386A1 (en) * | 2009-11-13 | 2011-05-19 | Oral Delivery Technology Ltd. | Composition and prophylactic device for enhancing sexual performance or pleasure |
WO2012018324A1 (en) * | 2010-08-02 | 2012-02-09 | Athena Cosmetics, Inc. | Composition, method and kit for enhancing hair |
CN103079535A (en) * | 2010-08-02 | 2013-05-01 | 医药专利控股公司 | Composition, method and kit for enhancing hair |
AU2010358560B2 (en) * | 2010-08-02 | 2015-02-12 | Ac Patent Holding Inc. | Composition, method and kit for enhancing hair |
CN103079535B (en) * | 2010-08-02 | 2016-10-12 | Ac专利控股公司 | For strengthening the compositions of hair, method and test kit |
US8361994B2 (en) | 2011-03-07 | 2013-01-29 | Merck Sharp & Dohme Corp | Primary amine diazeniumdiolate heterocyclic derivatives |
CN102675404A (en) * | 2012-05-10 | 2012-09-19 | 福建天泉药业股份有限公司 | Preparation method of glycyrrhetinic acid butyl nitrate |
CN102675404B (en) * | 2012-05-10 | 2014-04-09 | 福建天泉药业股份有限公司 | Preparation method of glycyrrhetinic acid butyl nitrate |
US10280138B2 (en) | 2015-03-31 | 2019-05-07 | Nicox S.A. | Nitric oxide donating derivatives of fluprostenol |
WO2016156104A1 (en) | 2015-03-31 | 2016-10-06 | Nicox S.A. | Nitric oxide donating derivatives of latanoprost free acid |
EP3088388A1 (en) | 2015-04-30 | 2016-11-02 | NicOx S.A. | Nitric oxide donating derivatives of prostaglandins |
US9956302B2 (en) | 2015-09-22 | 2018-05-01 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
US10098965B2 (en) | 2015-09-22 | 2018-10-16 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
US10111964B2 (en) | 2015-09-22 | 2018-10-30 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
US10117950B2 (en) | 2015-09-22 | 2018-11-06 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
US10159747B2 (en) | 2015-09-22 | 2018-12-25 | Graybug Visioon, Inc. | Compounds and compositions for the treatment of ocular disorders |
US9808531B2 (en) | 2015-09-22 | 2017-11-07 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
US10485876B2 (en) | 2015-09-22 | 2019-11-26 | Graybug Vision, Inc. | Compounds and compositions for the treatment of ocular disorders |
WO2018087092A1 (en) | 2016-11-08 | 2018-05-17 | Bausch & Lomb Incorporated | Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma |
Also Published As
Publication number | Publication date |
---|---|
JP2009500315A (en) | 2009-01-08 |
EP1917239A1 (en) | 2008-05-07 |
CA2613010A1 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2004313688B2 (en) | Prostaglandin nitrooxyderivatives | |
EP1917239A1 (en) | Fluoroprostaglandins nitroderivatives | |
US7718656B2 (en) | Prostaglandin derivatives | |
WO2018087092A1 (en) | Nitric oxide releasing prostaglandin derivatives for treating normal tension glaucoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2613010 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008518997 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006765591 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2006765591 Country of ref document: EP |